Fig. 1.

Serum ILF2 protein levels in different groups of subjects and subgroups of gastric cancer. a: ILF2 levels in three groups of subjects; b: ILF2 levels in different types of BGD and their comparisons with early stage GC and HC groups; c-g ILF2 levels in various subgroups of gastric cancer. In the subgroup analysis, the following subgroups were not shown due to small sample size: chronic gastritis (n = 4), ectopic pancreas (n = 3) and gastric ulcer (n = 2) for BGD (b), and MAC (n = 3) and PAC (n = 1) for histological type (c); there were missing samples in the following subgroups: 3 cases for Lauren’s type (d), 2 cases for pT stage (e), 3 cases for pN stage (f), and 2 cases for pTNM stage (g). ILF2, interleukin enhancer-binding factor 2; GC, gastric cancer; BGD, benign gastric disease; HC, healthy control; GIST, gastrointestinal stromal tumor; TAC, tubular adenocarcinoma; PCC, poorly cohesive carcinoma; pT, pathological T; pN, pathological N; pTNM, pathological TNM. *p < 0.05; **** p < 0.0001; ns, no significance